Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Sofosbuvir-Nutzenbewertung gemäß § 35a SGB V des G-BA, IQWiG-Bericht Nr. 219

doi:10.1055/s-0033-1362590

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2014; 52(7): 757-761
DOI: 10.1055/s-0033-1362590

Mitteilungen der DGVS

Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Sofosbuvir-Nutzenbewertung gemäß § 35a SGB V des G-BA, IQWiG-Bericht Nr. 219

Abstract

Volltext

Referenzen

Literaturverzeichnis
1 Younossi ZM, Stepanova M, Nader F et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology (Baltimore, Md) 2014;
2 Younossi ZM, Stepanova M, Zeuzem S et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. Journal of hepatology 2014;
3 Kowdley KV, Lawitz E, Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107
4 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877
5 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
6 Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N Engl J Med 2014;
7 Lawitz E, Poordad F, Kowdley KV et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C / C patients with chronic hepatitis C genotype 1. Journal of hepatology 2013; 59: 18-23
8 Naggie S. Sofosbuvir in HIV coinfection with HCV GT 1,2,3 PHOTON-1 trial. 21th CROI 2014; Abstract 26.
9 Rodriguez-Torres MR-OJ, Gaggar A, Shen G et al. Sofosbuvir and peginterferon alfa-2a / ribavirin for treatment-naive genotype 1–4 HCV-infected patients who are coinfected with HIV. Infectious Disease Week 2014 2014 Abstract.
10 EASL. Recommendations on Treatment of Hepatitis C 2014. Journal of hepatology 2014;
11 Miller MH, Agarwal K, Austin A et al. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy. Alimentary pharmacology & therapeutics 2014;
12 AASLD / IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org 02/28/2014.
13 http://www.dgvs.de/leitlinien/aktuelle-empfehlungen.
14 Lee MH, Yang HI, Lu SN et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. The Journal of infectious diseases 2012; 206: 469-477
15 Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke; a journal of cerebral circulation 2010; 41 (12) 2894-2900
16 Cowie BC, Allard N, MacLachlan JH. EUROPEAN RESPONSES IN FOCUS: COMPARING VIRAL HEPATITIS AND HIV RELATED DEATHS IN EUROPE 1990–2010 IN THE GLOBAL BURDEN OF DISEASE STUDY 2010. J Hepatol 2014; 60 (Suppl. 01) S35A
17 Ly KN, Xing J, Klevens RM et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278
18 Razavi H, Waked I, Sarrazin C et al. The present and future disease burden of hepatitis C virus (HCV) infection with today‘s treatment paradigm. Journal of viral hepatitis 2014; 21 (Suppl. 01) 34-59
19 Davis GL, Alter MJ, El-Serag H et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521 , 21.e1–6.
20 Morgan RL, Baack B, Smith BD et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337
21 Backus LI, Boothroyd DB, Phillips BR et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2011; 9: 509-516.e1
22 van der Meer AJ, Wedemeyer H, Feld JJ et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. Journal of hepatology 2014; 60: 191-196
23 Innes HA, Hutchinson SJ, Allen S et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011; 54: 1547-1558
24 Deuffic-Burban S, Deltenre P, Buti M et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143: 974-985.e14
25 Wedemeyer H, Duberg AS, Buti M et al. Strategies to manage hepatitis C virus (HCV) disease burden. Journal of viral hepatitis 2014; 21 (Suppl. 01) 60-89
26 Sarrazin C, Berg T, Ross RS et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289-351
27 GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH HEPATITIS INFECTION (www.who.int). World Health Organisation. 2014
28 Wiese M, Fischer J, Lobermann M et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 2014; 59: 49-57
29 Niederau C, Huppe D, Zehnter E et al. Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. World journal of gastroenterology : WJG 2012; 18: 1339-1347
30 Hezode C, Fontaine H, Dorival C et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. Journal of hepatology 2013; 59: 434-441
31 Curry MP FX, Chung R, Terrault N et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58 (suppl): 314A
32 Kim B, Trivedi A, Thung SN et al. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Seminars in liver disease 2014; 34: 108-112
33 Samuel DCM, Gane E et al. SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. J Hepatol 2014; 60 (Suppl. 01) S35A
34 Schaefer M, Sarkar R, Knop V et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012; 157: 94-103